Drug ID:Drug154
Drug Name:GSK2982772
CID:77108121
DrugBank ID:DB16875
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT02903966
Molecular Formula:C20H19N5O3
Molecular Weight:377.4 g/mol
Isomeric SMILES:CN1C2=CC=CC=C2OC[C@@H](C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
Synonyms:GSK2982772; 1622848-92-3; (S)-3-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-5-carboxamide; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; T5W3M0VO9B; CHEMBL4071864; 1622848-92-3 (free base); 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydro-1,5-Benzoxazepin-3-Yl]-1h-1,2,4-Triazole-5-Carboxamide
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1198 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) 28151659 Inhibition
dt1199 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) 34389633 Receptor-interacting serine/threonine-protein kinase 1 inhibitor
dt1200 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) Inhibitor
dt1201 77108121 (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide 8737 RIPK1 Homo sapiens (human) 28151659 Inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT02302404 A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects PHASE1 COMPLETED GlaxoSmithKline Inflammatory Bowel Diseases DRUG: GSK2982772 solution; DRUG: GSK2982772 capsu… Details
NCT02903966 GSK2982772 Study in Subjects With Ulcerative Colitis PHASE2 COMPLETED GlaxoSmithKline Colitis, Ulcerative DRUG: GSK2982772|DRUG: Placebo Details
NCT04857112 Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Bausch Health Americas, Inc. Ulcerative Colitis DRUG: Low Dose MT-1303|DRUG: High Dose MT-1303|DR… Details
NCT02447302 Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis PHASE2 COMPLETED Arena Pharmaceuticals Ulcerative Colitis DRUG: Etrasimod|DRUG: Placebo Details
NCT02762500 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis PHASE2 COMPLETED Lycera Corp. Colitis, Ulcerative DRUG: LYC-30937-EC|DRUG: Placebo Details
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) PHASE2 TERMINATED Nektar Therapeutics Colitis, Ulcerative DRUG: LY3471851|DRUG: Placebo Details
NCT03849599 A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis PHASE1 COMPLETED Provention Bio, Inc. Ulcerative Colitis BIOLOGICAL: PRV-300|BIOLOGICAL: Placebo Details
NCT02611830 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis PHASE3 COMPLETED Takeda Colitis, Ulcerative DRUG: Vedolizumab 300 mg IV|DRUG: Placebo IV|DRUG… Details
NCT05807971 Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects PHASE1 COMPLETED Athos Therapeutics Inc Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… DRUG: ATH-063|DRUG: Placebo Details
NCT02039505 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis PHASE3 COMPLETED Takeda Ulcerative Colitis DRUG: Vedolizumab|DRUG: Vedolizumab placebo Details
NCT05076175 A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis PHASE2|PHASE3 RECRUITING Bristol-Myers Squibb Colitis, Ulcerative DRUG: Ozanimod Details
NCT06636656 A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis PHASE2 RECRUITING Boehringer Ingelheim Ulcerative Colitis DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… Details
NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) PHASE2 ACTIVE_NOT_RECRUITING Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Ulcerative Colitis DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… Details
NCT01959282 A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis PHASE2 COMPLETED Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… Details
NCT06381518 Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease None ENROLLING_BY_INVITATION Zuyderland Medisch Centrum IBD|Infliximab|Crohn Disease|Ulcerative Colitis OTHER: Switch to SC CT-P13. Details
NCT00628433 Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis PHASE1|PHASE2 COMPLETED Harbor Therapeutics Ulcerative Colitis DRUG: Placebo|DRUG: HE3286 Details
NCT01877577 Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D None COMPLETED University of California, San Francisco Crohn's Disease (CD)|Ulcerative Colitis (UC) DIETARY_SUPPLEMENT: Vitamin D3 Details
NCT00317356 A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis PHASE2 TERMINATED Otsuka Pharmaceutical Co., Ltd. Colitis, Ulcerative DRUG: OPC-6535(Tetomilast) Details
NCT05019742 Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis PHASE2 RECRUITING Shanghai Pharma Biotherapeutics USA Inc. Ulcerative Colitis DRUG: SPH3127|DRUG: Placebo Details
NCT02601300 An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis PHASE2 COMPLETED Celgene Colitis, Ulcerative DRUG: GED-0301 Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patient…

PMID: 34389633
Year: 2021
Relationship Type: Treatment Score: 7.5

OBJECTIVE: Tumour necrosis factor signalling via the receptor-interacting protein kinase 1 (RIPK1) pathway regulates colonic inflammation suggesting …

View Details
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Spec…

PMID: 28151659
Year: 2017
Relationship Type: Treatment Score: 6.3

RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediat…

View Details